Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Useful takeaways from this story.
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.